CHICAGO, June 9, 2025 — On Monday, June 9, NewAmsterdam Pharma Company announced positive results from an Alzheimer’s disease blood biomarkers sub-study of the 52-week Phase 3 BROADWAY clinical trial of its LDL cholesterol lowering drug, obicetrapib.

Full results from the Alzheimer’s sub-study are scheduled to be reported Wednesday, July 30 at the Alzheimer’s Association International Conference (AAIC) 2025 in Toronto and online.

“Today’s report from NewAmsterdam is incredibly promising and points to a future of powerful combination therapies that address the key aspects of the disease from a variety of angles, and the distinct possibility of effective prevention strategies. We are proud that results like this are catalyzed by one of the Alzheimer’s Association’s investments,” said Joanne Pike, DrPH, Alzheimer’s Association president and CEO.

“Looking at these results as well as previous studies of this drug, we see a relatively safe and inexpensive oral drug with an effect on LDL-C and significant reduction of Alzheimer’s underlying biology. This is another opportunity to explore how cardiovascular health and treatment could contribute to Alzheimer’s prevention,” said Maria C. Carrillo, Ph.D., Alzheimer’s Association chief science officer and medical affairs lead.

Reducing the progression of Alzheimer’s biomarkers suggests the potential to significantly alter the course of the disease, certainly in the studied population — people with heart disease, and ApoE4 carriers — and perhaps beyond. The connection between the health of one’s cardiovascular system and the health of the brain are well-known and well-established, so this route of addressing the disease has great potential.

In April 2023, the Alzheimer’s Association announced a commitment of €10 million ($10.85 million) to EQT Life Sciences’ LSP Dementia Fund, an international venture capital fund that invests in companies developing promising, high-impact treatments for Alzheimer’s and other neurodegenerative diseases. The first investment by the LSP Dementia Fund was in NewAmsterdam Pharma.

Investments such as this clearly and convincingly demonstrate how the Alzheimer’s Association is expanding into more varied areas of dementia drug development to advance and diversify the pipeline and, eventually, expand the number and effectiveness of treatments available to people living with Alzheimer’s and all other diseases that cause dementia.

This is just one example of how the Alzheimer’s Association is accelerating innovation in Alzheimer’s and dementia treatment and prevention research. Others include:

• Part the Cloud initiative, which has generated more than $85 million for Alzheimer's research, and awarded 68 grants to some of the most exciting and innovative clinical trials.
• May 2025 strategic investment of $10 million in the Dementia Discovery Fund 2.
• AAIC and other premier global medical/scientific conferences.
• Alzheimer’s Association Research Roundtable, which brings together industry leaders with top scientists from around the world to discuss the development and management of new treatments.

About the Alzheimer's Association

The Alzheimer’s Association is a worldwide voluntary health organization dedicated to Alzheimer’s care, support and research. Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia®. Visit alz.org or call 800.272.3900.